Interestingly, the reduction of postprandial glycemic levelsinducedby sotagliflozin was also shown in T2DM patients with renal impairment(estimated glomerular filtration rate eGFR < 45 mL/min/1.73 m2), who usually show a decrement of UGE values; in addition,a clinically relevant reduction in blood pressure was also observedin this clinical trial.127 On the whole,these results suggested that dual SGLT-1/SGLT-2 inhibitors, such assotagliflozin, can provide a new therapeutic tool for the treatmentof T2DM patients with impaired renal function. The gene discussed is SLC5A1; the disease is type 2 diabetes mellitus.